Fund moves
13.4%Stake
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BGLC · NASDAQ · Services-Medical Laboratories
Bionexus Gene Lab (BGLC) · oqro.io/stocks/BGLC · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Bionexus Gene Lab is on record in SEC filings since 2006.
No open-market sale by an insider of Bionexus Gene Lab (BGLC) was filed with the SEC in the last 90 days.
No trade in Bionexus Gene Lab (BGLC) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$0.68+0.00 (0.00%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−84.4% (−$3.67) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $4.35 on Nov 20, 2025 to $0.68 on Nov 20, 2026 (−84.4%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Services-Medical Laboratories company based in Kuala Lumpur.
Last 12 months
−84.4%
Market value
$2.25M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 3,180 shares sold short (0.1% of shares outstanding), −64.9% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$7.42M
−21.9% vs the year before
Net income, fiscal 2025
−$2.98M
A loss for the year
Shares outstanding
2.93M
As of Aug 14, 2026
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Said its annual or quarterly report would be late
“The Company was adversely impacted by the Microsoft outage on Friday, November 13, 2026, and was unable to transmit the financials to its Edgar processing company in a timely manner. As a result, the Company’s Form 10-Q could not be timely filed without unreasonable effort or expense.”
NT 10-Q on sec.govSaid its annual or quarterly report would be late
“As previously disclosed, the Company undertook enhanced review of transactions in the 12 month period ended December 31, 2025 due to potential lapses in governance procedures as identified. As a result, the Company is unable to file by the prescribed due date without unreasonable effort or expense and expects to file on or before the fifteenth calendar day following the original due date, pursuant to Rule 12b-25(b).”
NT 10-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Revenue
$48K
−98.1% vs the same quarter a year earlier
Free cash flow, last 12 months
$129K
This quarter −$260K, a year earlier −$1.24M
Net cash
$811K
Debt $54K, cash $866K, at Sep 30, 2026
Net income, last 12 months
−$2.92M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 19, 2026. Quarterly reports are not audited. Read the filing
−97% on the same quarter a year earlier ($1.78M)
$0 the same quarter a year earlier
$78K the same quarter a year earlier
$357K the same quarter a year earlier
$108K the same quarter a year earlier
$193K the same quarter a year earlier
$31K the same quarter a year earlier
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Apr 14, 2026. Read the filing
−22% on the year before ($7.46M)
−11% on the year before ($762K)
−1.4% on the year before ($459K)
−58% on the year before ($572K)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 4,000 words.
BioNexus Gene Lab Corp. conducts operations through Chemrex Corporation Sdn. Bhd. and MRNA Scientific Sdn. Bhd. Chemrex is engaged in the distribution of industrial chemical raw materials, and MRNA Scientific is engaged in blood-based genomic screening services and related diagnostics activities. During fiscal year 2025, the Company’s results were affected primarily by lower sales volume at Chemrex, lower other income compared to fiscal year 2024 due mainly to a smaller reversal of expected credit losses, higher holding-company general and administrative expenses, and financing and strategic transactions involving Fidelion Diagnostics Pte. Ltd., ARC Group International Ltd., and the Company’s at-the-market offering program.
Source: SEC EDGAR, Form 10-K filed Apr 14, 2026 and Form 10-Q filed Nov 19, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
−17% on the year before ($138K)
−14% on the year before ($123K)
And 23 more headings in the filing.
Latest annual report filed Apr 14, 2026, compared with the one filed Apr 15, 2025. Read the filing
From time to time, the Company may be involved in claims, disputes, investigations, or legal proceedings arising in the ordinary course of business. As previously disclosed, the Company has been reviewing certain historical transactions involving former officers of Chemrex Corporation Sdn. Bhd. and related governance and approval matters. That review remains ongoing, and the Company is continuing to assess whether any claims or legal actions should be pursued in connection with those matters.
Source: SEC EDGAR, Form 10-K filed Apr 14, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Against the S&P 500 over the year
Since Nov 14, 2025, BGLC is down 85.0% and the index fund is up 2.7%: 88 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much BGLC moves
Beta 1.4 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 245 trading days (1 = in step with it).
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Off-exchange trading: 65.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (3.0% on ATS, 62.0% with other brokers), above its 26-week average of 41.1%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (23.9%), LEVEL ATS (19.2%), THE BARCLAYS ATS (8.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.